Supplemental material, sj-docx-1-mso-10.1177_20552173231203816 for Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis by John Kramer, Ralf Linker, David Paling, Adam Czaplinski, Olaf Hoffmann, V Wee Yong, Noreen Barker, Amy Perrin Ross, Elisabeth Lucassen, Mohammad Gufran, Xixi Hu, Ronald Zielman, Gustavo Seifer and Patrick Vermersch in Multiple Sclerosis Journal – Experimental, Translational and Clinical</p
Supplemental material, sj-docx-1-msj-10.1177_13524585231189673 for Assessing heterogeneity of treatm...
Supplemental material, sj-docx-1-msj-10.1177_13524585231199084 for Vaccination frequency in people n...
Supplemental material, sj-docx-1-nnr-10.1177_15459683221124126 for Rehabilitation to Improve Gaze an...
Supplemental material, sj-docx-1-mso-10.1177_20552173231203816 for Tolerability of subcutaneous ofat...
Supplemental material, sj-docx-1-msj-10.1177_13524585211032348 for Sustained reduction of serum neur...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189671 for Improving the efficiency of clini...
Supplemental material, sj-docx-1-msj-10.1177_13524585211035740 for Ocrelizumab treatment for relapsi...
Supplemental material, sj-docx-1-msj-10.1177_13524585221125382 for Recurrent disability progression ...
Supplemental material, sj-docx-2-msj-10.1177_13524585231189671 for Improving the efficiency of clini...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189678 for Enhancing involvement of people w...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189674 for Intermediate outcomes for clinica...
Supplemental material, sj-docx-2-msj-10.1177_13524585231189678 for Enhancing involvement of people w...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189677 for Enhancing diversity of clinical t...
Supplemental material, sj-docx-1-mso-10.1177_20552173221147620 for Axonal and myelin changes and the...
Supplemental material, sj-docx-1-msj-10.1177_13524585241226830 for Effectiveness of immunotherapies ...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189673 for Assessing heterogeneity of treatm...
Supplemental material, sj-docx-1-msj-10.1177_13524585231199084 for Vaccination frequency in people n...
Supplemental material, sj-docx-1-nnr-10.1177_15459683221124126 for Rehabilitation to Improve Gaze an...
Supplemental material, sj-docx-1-mso-10.1177_20552173231203816 for Tolerability of subcutaneous ofat...
Supplemental material, sj-docx-1-msj-10.1177_13524585211032348 for Sustained reduction of serum neur...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189671 for Improving the efficiency of clini...
Supplemental material, sj-docx-1-msj-10.1177_13524585211035740 for Ocrelizumab treatment for relapsi...
Supplemental material, sj-docx-1-msj-10.1177_13524585221125382 for Recurrent disability progression ...
Supplemental material, sj-docx-2-msj-10.1177_13524585231189671 for Improving the efficiency of clini...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189678 for Enhancing involvement of people w...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189674 for Intermediate outcomes for clinica...
Supplemental material, sj-docx-2-msj-10.1177_13524585231189678 for Enhancing involvement of people w...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189677 for Enhancing diversity of clinical t...
Supplemental material, sj-docx-1-mso-10.1177_20552173221147620 for Axonal and myelin changes and the...
Supplemental material, sj-docx-1-msj-10.1177_13524585241226830 for Effectiveness of immunotherapies ...
Supplemental material, sj-docx-1-msj-10.1177_13524585231189673 for Assessing heterogeneity of treatm...
Supplemental material, sj-docx-1-msj-10.1177_13524585231199084 for Vaccination frequency in people n...
Supplemental material, sj-docx-1-nnr-10.1177_15459683221124126 for Rehabilitation to Improve Gaze an...